Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

Core Viewpoint - Prime Medicine, Inc. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, representing an earnings surprise of -13.89% [1][2] Financial Performance - The company posted revenues of $1.12 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 59.6%, compared to zero revenues a year ago [2] - Over the last four quarters, Prime Medicine has surpassed consensus EPS estimates only once [2] Stock Performance - Prime Medicine shares have increased by approximately 39.4% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $2.59 million, and for the current fiscal year, it is -$1.30 on revenues of $7.74 million [7] - The estimate revisions trend for Prime Medicine was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Prime Medicine belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]